Opus Genetics, Inc.
IRDNASDAQHealthcare● Active
$4.03
+$0.00(+0.00%)
Market Cap$328024022
P/E Ratio—
52W High$5.81
52W Low$0.9
Opus Genetics, Inc. (IRD) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · IRD · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $14.20M | $10.99M | $19.05M | $39.85M | $0.59M |
| Cost of Revenue | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $14.20M | $10.99M | $19.05M | $39.85M | $0.59M |
| Gross Margin %(computed) | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $30.81M | $26.85M | $17.65M | $14.36M | $15.17M |
| G&A Expenses | $21.98M | $18.21M | $11.96M | $7.27M | $8.12M |
| Total Operating Expenses | $52.80M | $73.07M | $29.61M | $21.62M | $23.29M |
| Operating Income | ($38.60M) | ($62.07M) | ($10.56M) | $18.23M | ($22.70M) |
| Operating Margin %(computed) | -271.90% | -564.72% | -55.45% | 45.74% | — |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Interest Expense | $1.47M | $0.00M | $1.33M | $0.01M | $0.00M |
| Income Before Tax | ($49.59M) | ($57.53M) | ($9.97M) | $18.20M | ($56.69M) |
| Income Tax Expense | $0.00M | $0.00M | $0.01M | $0.32M | $0.00M |
| Net Income | ($49.59M) | ($57.53M) | ($9.99M) | $17.89M | ($56.69M) |
| Net Margin %(computed) | -349.33% | -523.40% | -52.42% | 44.89% | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.80 | $-2.15 | $-0.46 | $0.90 | $-3.82 |
| Wtd Avg Shares | 622.22M | 26.72M | 21.59M | 19.93M | 14.85M |
| EBITDA | ($48.07M) | ($57.52M) | ($9.97M) | $18.22M | ($56.69M) |
| EBITDA Margin %(computed) | -338.63% | -523.31% | -52.33% | 45.71% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Opus Genetics, Inc. data
About Opus Genetics, Inc. (IRD) Income Statement
Opus Genetics, Inc. (IRD) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, IRD reported revenue of $0.01B, gross profit of $0.01B (gross margin 100.00%), and net income of ($0.05B) — a net profit margin of -349.33%.
Frequently asked questions
IRD · 4 questionsOpus Genetics, Inc. (IRD) reported revenue of $0.01B for 2025, up 29.1% year-over-year.
IRD revenueIRD salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09